Username

Password

Forgot Password?

Preview

Sign-in free and Explore the Exciting World of BiomedExperts:

Over 1.500.000 Profiles
More than 1.800 Organizations worldwide
State of the Art Network Visualizations

Manage your own Profile
Locate Experts in your Country/Region
Locate Experts in your 1. and 2. Level Network
Connect to Experts Worldwide

NetworkView

Attila Nagy

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Chemicals & Drugs

Living Beings

Anatomy

Cultured Tumor Cells

Procedures

Physiology

Cell Division

Disorders

Prostatic Neoplasms

Sign-in to see full Profile

Network (preview)

Co-Publications
Name
74
Schally, Andrew
53
Halmos, Gabor
26
Szepeshazi, Karoly
19
Groot, Kate
13
Plonowski, Artur
11
Keller, Gunhild
11
Engel, Jörg
9
Sun, Baodong
9
Armatis, Patricia
8
Arencibia, Jose
8
Baker, Ben
7
Hebert, Francine
6
Bajo, Ana
6
Kiaris, Hippokratis
6
Kovacs, Magdolna

Sign-in to see all Coauthors

Publications

TOP 3
Keller Gunhild; Schally Andrew V; Nagy Attila; Baker Benjamin; Halmos Gabor; Engel Jörg B
Effective therapy of experimental human malignant melanomas with a targeted cytotoxic somatostatin analogue without induction of multi-drug resistance proteins.
Stangelberger Anton; Schally Andrew V; Nagy Attila; Szepeshazi Karoly; Kanashiro Celia A; Halmos Gabor
Inhibition of human experimental prostate cancers by a targeted cytotoxic luteinizing hormone-releasing hormone analog AN-207.
Stangelberger Anton; Schally Andrew V; Letsch Markus; Szepeshazi Karoly; Nagy Attila; Halmos Gabor; Kanashiro Celia A; Corey Eva; Vessella Robert
Targeted chemotherapy with cytotoxic bombesin analogue AN-215 inhibits growth of experimental human prostate cancers.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Attila Nagy (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2006: Keller Gunhild; Schally Andrew V; Nagy Attila; Baker Benjamin; Halmos Gabor; Engel Jörg B
Effective therapy of experimental human malignant melanomas with a targeted cytotoxic somatostatin analogue without induction of multi-drug resistance proteins.
International journal of oncology 2006;28(6):1507-13.
2006: Stangelberger Anton; Schally Andrew V; Nagy Attila; Szepeshazi Karoly; Kanashiro Celia A; Halmos Gabor
Inhibition of human experimental prostate cancers by a targeted cytotoxic luteinizing hormone-releasing hormone analog AN-207.
The Prostate 2006;66(2):200-10.
2006: Stangelberger Anton; Schally Andrew V; Letsch Markus; Szepeshazi Karoly; Nagy Attila; Halmos Gabor; Kanashiro Celia A; Corey Eva; Vessella Robert
Targeted chemotherapy with cytotoxic bombesin analogue AN-215 inhibits growth of experimental human prostate cancers.
International journal of cancer. Journal international du cancer 2006;118(1):222-9.
2005: Engel Jörg B; Schally Andrew V; Halmos Gabor; Baker Benjamin; Nagy Attila; Keller Gunhild
Targeted cytotoxic bombesin analog AN-215 effectively inhibits experimental human breast cancers with a low induction of multi-drug resistance proteins.
Endocrine-related cancer 2005;12(4):999-1009.
2005: Keller Gunhild; Schally Andrew V; Nagy Attila; Halmos Gabor; Baker Benjamin; Engel Jorg B
Targeted chemotherapy with cytotoxic bombesin analogue AN-215 can overcome chemoresistance in experimental renal cell carcinomas.
Cancer 2005;104(10):2266-74.
2005: Nagy Attila; Schally Andrew V
Targeting of cytotoxic luteinizing hormone-releasing hormone analogs to breast, ovarian, endometrial, and prostate cancers.
Biology of reproduction 2005;73(5):851-9.
2005: Szepeshazi Karoly; Schally Andrew V; Nagy Attila; Halmos Gabor
Inhibition of growth of experimental human and hamster pancreatic cancers in vivo by a targeted cytotoxic bombesin analog.
Pancreas 2005;31(3):275-82.
2005: Keller Gunhild; Schally Andrew V; Gaiser Timo; Nagy Attila; Baker Benjamin; Halmos Gabor; Engel Jörg B
Receptors for luteinizing hormone releasing hormone (LHRH) expressed in human non-Hodgkin's lymphomas can be targeted for therapy with the cytotoxic LHRH analogue AN-207.
European journal of cancer (Oxford, England : 1990) 2005;41(14):2196-202.
2005: Engel Jorg B; Schally Andrew V; Halmos Gabor; Baker Ben; Nagy Attila; Keller Gunhild
Targeted therapy with a cytotoxic somatostatin analog, AN-238, inhibits growth of human experimental endometrial carcinomas expressing multidrug resistance protein MDR-1.
Cancer 2005;104(6):1312-21.
2005: Keller Gunhild; Schally Andrew V; Gaiser Timo; Nagy Attila; Baker Benjamin; Halmos Gabor; Engel Jörg B
Receptors for luteinizing hormone releasing hormone expressed on human renal cell carcinomas can be used for targeted chemotherapy with cytotoxic luteinizing hormone releasing hormone analogues.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(15):5549-57.
2005: Engel Jörg B; Schally Andrew V; Halmos Gabor; Baker Benjamin; Nagy Attila; Keller Gunhild
Experimental therapy of human endometrial cancers with a targeted cytotoxic bombesin analog AN-215: low induction of multidrug resistance proteins.
European journal of cancer (Oxford, England : 1990) 2005;41(12):1824-30.
2005: Keller Gunhild; Schally Andrew V; Gaiser Timo; Nagy Attila; Baker Benjamin; Westphal Gabriela; Halmos Gabor; Engel Jörg B
Human malignant melanomas express receptors for luteinizing hormone releasing hormone allowing targeted therapy with cytotoxic luteinizing hormone releasing hormone analogue.
Cancer research 2005;65(13):5857-63.
2005: Kanashiro Celia A; Schally Andrew V; Nagy Attila; Halmos Gabor
Inhibition of experimental U-118MG glioblastoma by targeted cytotoxic analogs of bombesin and somatostatin is associated with a suppression of angiogenic and antiapoptotic mechanisms.
International journal of oncology 2005;27(1):169-74.
2005: Keller Gunhild; Engel Jörg B; Schally Andrew V; Nagy Attila; Hammann Brian; Halmos Gabor
Growth inhibition of experimental non-Hodgkin's lymphomas with the targeted cytotoxic somatostatin analogue AN-238.
International journal of cancer. Journal international du cancer 2005;114(5):831-5.
2005: Engel Jörg B; Keller Gunhild; Schally Andrew V; Nagy Attila; Chism David D; Halmos Gabor
Effective treatment of experimental human endometrial cancers with targeted cytotoxic luteinizing hormone-releasing hormone analogues AN-152 and AN-207.
Fertility and sterility 2005;83 Suppl 1():1125-33.
2005: Engel Jörg B; Keller Gunhild; Schally Andrew V; Halmos Gabor; Hammann Brian; Nagy Attila
Effective inhibition of experimental human ovarian cancers with a targeted cytotoxic bombesin analogue AN-215.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(6):2408-15.
2005: Nagy A; Schally A V
Targeting cytotoxic conjugates of somatostatin, luteinizing hormone-releasing hormone and bombesin to cancers expressing their receptors: a "smarter" chemotherapy.
Current pharmaceutical design 2005;11(9):1167-80.
2004: Schally Andrew V; Nagy Attila
Chemotherapy targeted to cancers through tumoral hormone receptors.
Trends in endocrinology and metabolism: TEM 2004;15(7):300-10.
2004: Schally A V; Szepeshazi K; Nagy A; Comaru-Schally A M; Halmos G
New approaches to therapy of cancers of the stomach, colon and pancreas based on peptide analogs.
Cellular and molecular life sciences : CMLS 2004;61(9):1042-68.
2003: Letsch Markus; Schally Andrew V; Szepeshazi Karoly; Halmos Gabor; Nagy Attila
Preclinical evaluation of targeted cytotoxic luteinizing hormone-releasing hormone analogue AN-152 in androgen-sensitive and insensitive prostate cancers.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(12):4505-13.
2003: Szepeshazi Karoly; Schally Andrew V; Nagy Attila; Wagner Brady W; Bajo Ana Maria; Halmos Gabor
Preclinical evaluation of therapeutic effects of targeted cytotoxic analogs of somatostatin and bombesin on human gastric carcinomas.
Cancer 2003;98(7):1401-10.
2003: Bajo Ana M; Schally Andrew V; Halmos Gabor; Nagy Attila
Targeted doxorubicin-containing luteinizing hormone-releasing hormone analogue AN-152 inhibits the growth of doxorubicin-resistant MX-1 human breast cancers.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(10 Pt 1):3742-8.
2003: Szereday Zoltan; Schally Andrew V; Szepeshazi Karoly; Bajo Ana-Maria; Hebert Francine; Halmos Gabor; Nagy Attila
Effective treatment of H838 human non-small cell lung carcinoma with a targeted cytotoxic somatostatin analog, AN-238.
International journal of oncology 2003;22(5):1141-6.
2003: Halmos Gabor; Schally Andrew V; Comaru-Schally Ana Maria; Nagy Attila; Irimpen Anand
Absence of binding of targeted analogs of somatostatin carrying cytotoxic radicals or radionuclides to growth hormone secretagogue receptors on human myocardium.
Life sciences 2003;72(23):2669-74.
2003: Schally Andrew V; Nagy Attila
New approaches to treatment of various cancers based on cytotoxic analogs of LHRH, somatostatin and bombesin.
Life sciences 2003;72(21):2305-20.
2002: Arencibia Jose M; Bajo Ana M; Schally Andrew V; Krupa Magdalena; Chatzistamou Ioulia; Nagy Attila
Effective treatment of experimental ES-2 human ovarian cancers with a cytotoxic analog of luteinizing hormone-releasing hormone AN-207.
Anti-cancer drugs 2002;13(9):949-56.
2002: Szereday Z; Schally A V; Nagy A; Plonowski A; Bajo A M; Halmos G; Szepeshazi K; Groot K
Effective treatment of experimental U-87MG human glioblastoma in nude mice with a targeted cytotoxic bombesin analogue, AN-215.
British journal of cancer 2002;86(8):1322-7.
2002: Szepeshazi Karoly; Schally Andrew V; Halmos Gabor; Armatis Patricia; Hebert Francine; Sun Baodong; Feil Anita; Kiaris Hippokratis; Nagy Attila
Targeted cytotoxic somatostatin analogue AN-238 inhibits somatostatin receptor-positive experimental colon cancers independently of their p53 status.
Cancer research 2002;62(3):781-8.
2002: Plonowski Artur; Schally Andrew V; Nagy Attila; Groot Kate; Krupa Magdalena; Navone Nora M; Logothetis Christopher
Inhibition of in vivo proliferation of MDA-PCa-2b human prostate cancer by a targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207.
Cancer letters 2002;176(1):57-63.
2002: Plonowski Artur; Schally Andrew V; Nagy Attila; Sun Baodong; Halmos Gabor
Effective treatment of experimental DU-145 prostate cancers with targeted cytotoxic somatostatin analog AN-238.
International journal of oncology 2002;20(2):397-402.
2002: Kovacs M; Schally A V; Csernus B; Busto R; Rekasi Z; Nagy A
Targeted cytotoxic analogue of luteinizing hormone-releasing hormone (LH-RH) only transiently decreases the gene expression of pituitary receptors for LH-RH.
Journal of neuroendocrinology 2002;14(1):5-13.
2001: Schally A V; Comaru-Schally A M; Nagy A; Kovacs M; Szepeshazi K; Plonowski A; Varga J L; Halmos G
Hypothalamic hormones and cancer.
Frontiers in neuroendocrinology 2001;22(4):248-91.
2001: Plonowski A; Schally A V; Koppan M; Nagy A; Arencibia J M; Csernus B; Halmos G
Inhibition of the UCI-107 human ovarian carcinoma cell line by a targeted cytotoxic analog of somatostatin, AN-238.
Cancer 2001;92(5):1168-76.
2001: Szepeshazi K; Schally A V; Halmos G; Sun B; Hebert F; Csernus B; Nagy A
Targeting of cytotoxic somatostatin analog AN-238 to somatostatin receptor subtypes 5 and/or 3 in experimental pancreatic cancers.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(9):2854-61.
2001: Arencibia J M; Schally A V; Krupa M; Bajo A M; Nagy A; Szepeshazi K; Plonowski A
Targeting of doxorubicin to ES-2 human ovarian cancers in nude mice by linking to an analog of luteinizing hormone-releasing hormone improves its effectiveness.
International journal of oncology 2001;19(3):571-7.
2001: Kiaris H; Schally A V; Nagy A; Szepeshazi K; Hebert F; Halmos G
A targeted cytotoxic somatostatin (SST) analogue, AN-238, inhibits the growth of H-69 small-cell lung carcinoma (SCLC) and H-157 non-SCLC in nude mice.
European journal of cancer (Oxford, England : 1990) 2001;37(5):620-8.
2001: Arencibia J M; Schally A V; Halmos G; Nagy A; Kiaris H
In vitro targeting of a cytotoxic analog of luteinizing hormone-releasing hormone AN-207 to ES-2 human ovarian cancer cells as demonstrated by microsatellite analyses.
Anti-cancer drugs 2001;12(1):71-8.
2000: Plonowski A; Nagy A; Schally A V; Sun B; Groot K; Halmos G
In vivo inhibition of PC-3 human androgen-independent prostate cancer by a targeted cytotoxic bombesin analogue, AN-215.
International journal of cancer. Journal international du cancer 2000;88(4):652-7.
2000: Halmos G; Sun B; Schally A V; Hebert F; Nagy A
Human ovarian cancers express somatostatin receptors.
The Journal of clinical endocrinology and metabolism 2000;85(10):3509-12.
2000: Chatzistamou L; Schally A V; Nagy A; Armatis P; Szepeshazi K; Halmos G
Effective treatment of metastatic MDA-MB-435 human estrogen-independent breast carcinomas with a targeted cytotoxic analogue of luteinizing hormone-releasing hormone AN-207.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(10):4158-65.
2000: Schally A V; Comaru-Schally A M; Plonowski A; Nagy A; Halmos G; Rekasi Z
Peptide analogs in the therapy of prostate cancer.
The Prostate 2000;45(2):158-66.
2000: Plonowski A; Schally A V; Nagy A; Kiaris H; Hebert F; Halmos G
Inhibition of metastatic renal cell carcinomas expressing somatostatin receptors by a targeted cytotoxic analogue of somatostatin AN-238.
Cancer research 2000;60(11):2996-3001.
2000: Kahán Z; Nagy A; Schally A V; Halmos G; Arencibia J M; Groot K
Administration of a targeted cytotoxic analog of luteinizing hormone-releasing hormone inhibits growth of estrogen-independent MDA-MB-231 human breast cancers in nude mice.
Breast cancer research and treatment 2000;59(3):255-62.
2000: Kiaris H; Schally A V; Nagy A; Sun B; Szepeshazi K; Halmos G
Regression of U-87 MG human glioblastomas in nude mice after treatment with a cytotoxic somatostatin analog AN-238.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(2):709-17.
2000: Nagy A; Plonowski A; Schally A V
Stability of cytotoxic luteinizing hormone-releasing hormone conjugate (AN-152) containing doxorubicin 14-O-hemiglutarate in mouse and human serum in vitro: implications for the design of preclinical studies.
Proceedings of the National Academy of Sciences of the United States of America 2000;97(2):829-34.
1999: Kiaris H; Schally A V; Nagy A; Sun B; Armatis P; Szepeshazi K
Targeted cytotoxic analogue of bombesin/gastrin-releasing peptide inhibits the growth of H-69 human small-cell lung carcinoma in nude mice.
British journal of cancer 1999;81(6):966-71.
1999: Szepeshazi K; Schally A V; Nagy A
Effective treatment of advanced estrogen-independent MXT mouse mammary cancers with targeted cytotoxic LH-RH analogs.
Breast cancer research and treatment 1999;56(3):267-76.
1999: Kahán Z; Nagy A; Schally A V; Hebert F; Sun B; Groot K; Halmos G
Inhibition of growth of MX-1, MCF-7-MIII and MDA-MB-231 human breast cancer xenografts after administration of a targeted cytotoxic analog of somatostatin, AN-238.
International journal of cancer. Journal international du cancer 1999;82(4):592-8.
1999: Schally A V; Nagy A
Cancer chemotherapy based on targeting of cytotoxic peptide conjugates to their receptors on tumors.
European journal of endocrinology / European Federation of Endocrine Societies 1999;141(1):1-14.
1999: Kahán Z; Nagy A; Schally A V; Halmos G; Arencibia J M; Groot K
Complete regression of MX-1 human breast carcinoma xenografts after targeted chemotherapy with a cytotoxic analog of luteinizing hormone-releasing hormone, AN-207.
Cancer 1999;85(12):2608-15.
1999: Miyazaki M; Schally A V; Nagy A; Lamharzi N; Halmos G; Szepeshazi K; Armatis P
Targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 inhibits growth of OV-1063 human epithelial ovarian cancers in nude mice.
American journal of obstetrics and gynecology 1999;180(5):1095-103.
1999: Plonowski A; Schally A V; Nagy A; Sun B; Szepeshazi K
Inhibition of PC-3 human androgen-independent prostate cancer and its metastases by cytotoxic somatostatin analogue AN-238.
Cancer research 1999;59(8):1947-53.
1999: Halmos G; Nagy A; Lamharzi N; Schally A V
Cytotoxic analogs of luteinizing hormone-releasing hormone bind with high affinity to human breast cancers.
Cancer letters 1999;136(2):129-36.
1999: Koppán M; Nagy A; Schally A V; Plonowski A; Halmos G; Arencibia J M; Groot K
Targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 inhibits the growth of PC-82 human prostate cancer in nude mice.
The Prostate 1999;38(2):151-8.
1998: Koppan M; Nagy A; Schally A V; Arencibia J M; Plonowski A; Halmos G
Targeted cytotoxic analogue of somatostatin AN-238 inhibits growth of androgen-independent Dunning R-3327-AT-1 prostate cancer in rats at nontoxic doses.
Cancer research 1998;58(18):4132-7.
1998: Toth K; Kovacs M; Zarandi M; Halmos G; Groot K; Nagy A; Kele Z; Schally A V
New analogs of human growth hormone-releasing hormone (1-29) with high and prolonged antagonistic activity.
The journal of peptide research : official journal of the American Peptide Society 1998;51(2):134-41.
1998: Nagy A; Schally A V; Halmos G; Armatis P; Cai R Z; Csernus V; Kovács M; Koppán M; Szepesházi K; Kahán Z
Synthesis and biological evaluation of cytotoxic analogs of somatostatin containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin.
Proceedings of the National Academy of Sciences of the United States of America 1998;95(4):1794-9.
1997: Miyazaki M; Nagy A; Schally A V; Lamharzi N; Halmos G; Szepeshazi K; Groot K; Armatis P
Growth inhibition of human ovarian cancers by cytotoxic analogues of luteinizing hormone-releasing hormone.
Journal of the National Cancer Institute 1997;89(23):1803-9.
1997: Szepeshazi K; Schally A V; Nagy A; Halmos G; Groot K
Targeted cytotoxic luteinizing hormone releasing hormone (LH-RH) anlalogs inhibit growth of estrogen independent MXT mouse mammary cancers in vivo by decreasing cell proliferation and inducing apoptosis.
Anti-cancer drugs 1997;8(10):974-87.
1997: Kovacs M; Schally A V; Nagy A; Koppan M; Groot K
Recovery of pituitary function after treatment with a targeted cytotoxic analog of luteinizing hormone-releasing hormone.
Proceedings of the National Academy of Sciences of the United States of America 1997;94(4):1420-5.
1997: Nagy A; Armatis P; Cai R Z; Szepeshazi K; Halmos G; Schally A V
Design, synthesis, and in vitro evaluation of cytotoxic analogs of bombesin-like peptides containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin.
Proceedings of the National Academy of Sciences of the United States of America 1997;94(2):652-6.
1997: Zarandi M; Kovacs M; Horvath J E; Toth K; Halmos G; Groot K; Nagy A; Kele Z; Schally A V
Synthesis and in vitro evaluation of new potent antagonists of growth hormone-releasing hormone (GH-RH).
Peptides 1997;18(3):423-30.
1996: Nagy A; Schally A V; Armatis P; Szepeshazi K; Halmos G; Kovacs M; Zarandi M; Groot K; Miyazaki M; Jungwirth A; Horvath J
Cytotoxic analogs of luteinizing hormone-releasing hormone containing doxorubicin or 2-pyrrolinodoxorubicin, a derivative 500-1000 times more potent.
Proceedings of the National Academy of Sciences of the United States of America 1996;93(14):7269-73.
1996: Nagy A; Armatis P; Schally A V
High yield conversion of doxorubicin to 2-pyrrolinodoxorubicin, an analog 500-1000 times more potent: structure-activity relationship of daunosamine-modified derivatives of doxorubicin.
Proceedings of the National Academy of Sciences of the United States of America 1996;93(6):2464-9.
1996: Szepeshazi K; Schally A V; Halmos G; Szoke B; Groot K; Nagy A
Effect of a cytotoxic analog of LH-RH (T-98) on the growth of estrogen-dependent MXT mouse mammary cancers: correlations between growth characteristics and EGF receptor content of tumors.
Breast cancer research and treatment 1996;40(2):129-39.
1994: Zarandi M; Horvath J E; Halmos G; Pinski J; Nagy A; Groot K; Rekasi Z; Schally A V
Synthesis and biological activities of highly potent antagonists of growth hormone-releasing hormone.
Proceedings of the National Academy of Sciences of the United States of America 1994;91(25):12298-302.
1994: Szöke B; Horváth J; Halmos G; Rékási Z; Groot K; Nagy A; Schally A V
LH-RH analogue carrying a cytotoxic radical is internalized by rat pituitary cells in vitro.
Peptides 1994;15(2):359-66.
1993: Nagy A; Szoke B; Schally A V
Selective coupling of methotrexate to peptide hormone carriers through a gamma-carboxamide linkage of its glutamic acid moiety: benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate activation in salt coupling.
Proceedings of the National Academy of Sciences of the United States of America 1993;90(13):6373-6.
1993: Rékási Z; Szöke B; Nagy A; Groot K; Rékási E S; Schally A V
Effect of luteinizing hormone-releasing hormone analogs containing cytotoxic radicals on the function of rat pituitary cells: tests in a long term superfusion system.
Endocrinology 1993;132(5):1991-2000.
1993: Pinski J; Yano T; Janaky T; Nagy A; Juhasz A; Bokser L; Groot K; Schally A V
Evaluation of biological activities of new LH-RH antagonists (T-series) in male and female rats.
International journal of peptide and protein research 1993;41(1):66-73.
1993: Pinski J; Schally A V; Yano T; Szepeshazi K; Halmos G; Groot K; Comaru-Schally A M; Radulovic S; Nagy A
Inhibition of growth of experimental prostate cancer in rats by LH-RH analogs linked to cytotoxic radicals.
The Prostate 1993;23(2):165-78.
1992: Szepeshazi K; Schally A V; Juhasz A; Nagy A; Janaky T
Effect of luteinizing hormone-releasing hormone analogs containing cytotoxic radicals on growth of estrogen-independent MXT mouse mammary carcinoma in vivo.
Anti-cancer drugs 1992;3(2):109-16.
1992: Cai R Z; Radulovic S; Pinski J; Nagy A; Redding T W; Olsen D B; Schally A V
Pseudononapeptide bombesin antagonists containing C-terminal Trp or Tpi.
Peptides 1992;13(2):267-71.
1992: Radulovic S; Nagy A; Szoke B; Schally A V
Cytotoxic analog of somatostatin containing methotrexate inhibits growth of MIA PaCa-2 human pancreatic cancer xenografts in nude mice.
Cancer letters 1992;62(3):263-71.
1992: Janáky T; Juhász A; Bajusz S; Csernus V; Srkalovic G; Bokser L; Milovanovic S; Redding T W; Rékási Z; Nagy A
Analogues of luteinizing hormone-releasing hormone containing cytotoxic groups.
Proceedings of the National Academy of Sciences of the United States of America 1992;89(3):972-6.

Sign-in to see more